DRM 01 fails two Phase III trials for treatment of acne.- Dermira Inc.
Dermira Inc. announced that DRM 01 ( olumacostat glasaretil) failed to meet its co-primary endpoints in two Phase III trials, for treatment of acne, after 12 weeks of treatment. In both trials, olumacostat glasaretil demonstrated a reduction of 14.3 and 16.6 from baseline in inflammatory and non-inflammatory lesion counts, compared to 13.7 and 15.3 with placebo. Additionally, 19.1% and 16.3% of patients taking the drug achieved at least a two-grade improvement from baseline to a final grade of zero or one on the five-point Investigator�s Global Assessment (IGA) scale, compared to 20.8% and 11.8% with placebo.
Dermira expects it will discontinue development of the drug.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.